AlloVir and Kalaris enter merger to advance retinal disease therapies
AlloVir has entered into a definitive agreement for the acquisition of the complete outstanding shares of Kalaris Therapeutics, to create…
Deal News
-
-
NLS and Kadimastem stocks soar following merger agreement
Switzerland-based NLS Pharmaceutics and Israel-headquartered Kadimastem have signed a definitive merger agreement, with plans to form a joint biopharmaceutical aimed…
-
Matinas BioPharma mulls wind-down as antifungal therapy deal falls through
Matinas BioPharma has halted all product development activities and fired 80% of its staff, including three members of senior management,…
-
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline
Lyell Immunopharma has entered a definitive agreement to acquire ImmPACT Bio, a privately-owned clinical-stage biotechnology company specialising in chimeric antigen…
-
MSD acquires cancer therapeutics developer Modifi Biosciences
MSD has acquired US cancer therapeutics developer Modifi Biosciences, a Yale University spinout, enhancing its portfolio with preclinical compounds designed…
-
DPV set to acquire Lumos Pharma for $38m
Double Point Ventures (DPV) has entered a definitive merger agreement to acquire all outstanding shares of Lumos Pharma for $38m.…
-
Ocuphire and Opus Genetics merge to develop IRD gene therapy
Ocuphire Pharma has announced the acquisition of Opus Genetics to create a biotech company dedicated to gene therapy development for…
-
MSD ventures into fibroblast therapies with $1.9bn deal with Mestag
MSD (Merck & Co) has signed a license and collaboration agreement with Mestag Therapeutics to develop new fibroblast therapies for…
-
ProductLife boosts drug development with IntiQuan acquisition
ProductLife Group (PLG) has announced the acquisition of IntiQuan, a Swiss firm specialising in pharmacometrics. The move enhances PLG's capabilities…
-
OnKure and Reneo Pharmaceuticals complete merger
OnKure has announced the successful completion of its merger with Reneo Pharmaceuticals, with the combined entity set to operate under…
